AVR

Anteris Technologies Global Corp. Common Stock

4.95 USD
-0.56
10.16%
At close Apr 30, 4:00 PM EDT
1 day
-10.16%
5 days
10.00%
1 month
35.99%
3 months
-17.22%
6 months
-11.61%
Year to date
-10.81%
1 year
-11.61%
5 years
-11.61%
10 years
-11.61%
 

About: Anteris Technologies Global Corp. is a structural heart company committed to discovering, developing and commercializing medical devices designed to improve the quality of life for patients with aortic stenosis. Its product, the DurAVR THV system, represents a product opportunity in a new THV class of single-piece heart valves, for the treatment of aortic stenosis. Its DurAVR THV system consists of a single-piece, biomimetic valve made with its proprietary ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold.

0
Funds holding %
of 7,425 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

45.27% more ownership

Funds ownership: 0% [Q3] → 45.27% (+45.27%) [Q4]

Research analyst outlook

We haven’t received any recent analyst ratings for AVR.

Financial journalist opinion

We haven’t received any recent news articles for AVR.

Charts implemented using Lightweight Charts™